A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis

Clinical Studies - May 22, 2023 - May 22, 2026

Ongoing

Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana

A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants with Systemic Sclerosis

Clinical Studies - Apr 14, 2023 - Apr 14, 2026

Ongoing

Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana

A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase3 trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo,in combination with a glucocorticoid taper regimen, in patients with po...

Clinical Studies - Mar 10, 2023 - Mar 10, 2026

Ongoing

Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana

A randomized, four-arm, canakinumab placebo-controlled, participant, investigator and sponsor-blinded study investigating the safety, tolerability and efficacy of intra-articular canakinumab followed by intra-articular LNA043 in patients with knee os...

Clinical Studies - Dec 30, 2022 - Dec 31, 2025

Ongoing

Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Peischl Shirin, Bartz-Batliner Mira, Peischl Riana, Hutz Carina Liane

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

Clinical Studies - Nov 30, 2022 - Dec 31, 2025

Ongoing

Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Peischl Shirin, Peischl Riana, Bartz-Batliner Mira, Hutz Carina Liane

A double blind, randomized, placebo-controlled study to evaluate the efficacy and safety of PRA023 in Subject with Systemic Sclerosis associated with interstitial Lung Disease.

Clinical Studies - Aug 23, 2022 - Aug 23, 2024

Automatically Closed

Project leader: Rubbert-Roth Andrea
Members: Peischl Riana, Peischl Shirin, Bartz-Batliner Mira, Hutz Carina Liane, Schmiedeberg Kristin

A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper...

Clinical Studies - Jan 1, 2022 - Jan 1, 2025

Ongoing

Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Shirin, Gostic Dragana

Untersuchung der Sicherheit und Effektivität von mRNA basierten COVID-19 Impfungen bei Patienten mit rheumatoider Arthritis - ein exploratives Forschungsprojekt

Clinical Studies - Feb 1, 2021 - Dec 31, 2022

Completed

Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Riana, Peischl Shirin, Sasselli Clelia, Hutz Carina Liane

Upadacitinib treatment patterns, achievement of treatment targets and maintenance of response in moderate to severe Rheumatoid Arthritis patients in real-world practice

Clinical Studies - Aug 1, 2020 - Oct 31, 2023

Automatically Closed

Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Hutz Carina Liane, Peischl Riana, Peischl Shirin, Schmiedeberg Kristin

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease. So far, there is little evidence for the existence of specific biologic markers reliably indicating clinical activity and a rather wide panel of unspecific markers indica...

Fundamental Research - Apr 1, 2015 - Mar 31, 2018

Automatically Closed

Project leader: von Kempis Johannes
Members: Schmiedeberg Kristin